about
Cancer pharmacogenomics: strategies and challengesThe value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersGenetic causes of cancer predisposition in children and adolescentsTargeting cancer with kinase inhibitorsMetabolomics of Head and Neck Cancer: A Mini-ReviewSystems Biology in Kidney Transplantation: The Application of Multi-Omics to a Complex Model.DiSWOP: a novel measure for cell-level protein network analysis in localized proteomics image data.Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers.The Genome Conformation As an Integrator of Multi-Omic Data: The Example of Damage Spreading in CancerTranslating colorectal cancer prevention through the guanylyl cyclase C signaling axis.Structural mass spectrometry of tissue extracts to distinguish cancerous and non-cancerous breast diseases.Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agentsSystematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasisPrediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancerGenomic, Epigenomic, and Transcriptomic Profiling towards Identifying Omics Features and Specific Biomarkers That Distinguish Uterine Leiomyosarcoma and Leiomyoma at Molecular Levels.Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.From drug discovery to biomarker-driven clinical trials in lymphomaGenomic biomarkers for patient selection and stratification: the cancer paradigm.The use of 'Omics technology to rationally improve industrial mammalian cell line performance.An Optimal Mean Based Block Robust Feature Extraction Method to Identify Colorectal Cancer Genes with Integrated Data.Omics Profiling in Precision Oncology.Sample preparation method considerations for integrated transcriptomic and proteomic analysis of tumors.Flexible lab-tailored cut-offs for suitability of formalin-fixed tumor samples for diagnostic mutational analyses.Environmental influences in the etiology of colorectal cancer: the premise of metabolomics.Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin.mutation3D: Cancer Gene Prediction Through Atomic Clustering of Coding Variants in the Structural Proteome.Validation of whole-blood transcriptome signature during microdose recombinant human erythropoietin (rHuEpo) administration.Advances in omics for informed pharmaceutical research and development in the era of systems medicine.Enhancing GTEx by bridging the gaps between genotype, gene expression, and disease.Ensemble outlier detection and gene selection in triple-negative breast cancer data.Precision Medicine for Neonatal SepsisDiagnostic perspectives in the epoch of next-generation sequencing
P2860
Q24289309-9DBE92AB-FE42-4E32-8636-D3690485A03FQ26747403-915F17EC-0334-4671-969B-B80A11A4E1C4Q26770339-83DB9C1A-AB3C-48A6-86C7-C1736573BE18Q26865765-A5418ADF-DE2D-4FCC-80F3-C450ADACE5A9Q28069660-F80F9C14-A816-4B65-B9D7-37B05F55B05BQ30276752-0C0781BC-1694-4670-B4C0-288EAEDAD827Q30700969-06AA39AC-B634-4482-B01F-BEC567BA194CQ31028108-138721F2-17E7-47CB-86C1-7E621D6065C2Q31145202-549FCF88-31D3-4551-A21E-29F48F000665Q33722761-44758D00-CE30-48A1-945F-AAFAE92C62D9Q34282970-BB2A3408-9625-4557-9428-E1D8886C6EF3Q34554617-BCCB064F-51E8-4E00-84AC-DD1AC3C2C407Q35059602-74DE01D2-386F-4CBD-B270-DC77873D0B87Q35818215-62D00400-CDCD-45E2-83AB-B484DECEF1A8Q36448418-32C96DC1-E9E6-41D0-953B-EFED13250660Q37220383-3B308409-AAA1-4FDE-AECC-01B24E6DE6DFQ37225594-48E68CC9-8A99-41AA-A27B-F72BC4C3D9E8Q37551148-7003E49B-0914-4DE4-B8C5-3942EF80D46DQ38060203-91FC4E5E-AB6B-4E56-BCA0-0F09855BBED2Q38522584-602001BF-183B-4D8C-834A-681EAB88BE7FQ38619061-5387CC89-823B-4236-A95D-890A81CE96D1Q38813546-1A09C5D0-8853-482B-A4AE-F9F2971A0AC7Q39228035-AA590A05-78C0-4229-ACA4-34DEBE8847FBQ39284284-1E7ED42A-1D83-4C14-BA18-07128886E9D4Q39392886-6A3835A9-C49A-4C91-926E-5393A0212996Q39578254-927BC3D1-1701-437B-941E-406794638475Q40027634-718C9C30-B268-4153-A7BD-53777DD8FCBDQ47146367-DBA80F6D-0B19-4B98-9C69-97641C2D79B7Q50090705-811080DC-71DA-4D95-A6DC-B4583869D36FQ50093911-E255615E-89A0-4FE7-8655-71485B3588BFQ55113713-BCD0DC9A-7F84-4BF0-AC2D-931C3C8C0446Q57174545-2ADEF9FD-995F-4CEA-9427-9ED82EA3AAE1Q57338727-50E62D46-6CE4-4A72-A254-07AC5C7EB3AA
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Translating cancer 'omics' to improved outcomes.
@ast
Translating cancer 'omics' to improved outcomes.
@en
type
label
Translating cancer 'omics' to improved outcomes.
@ast
Translating cancer 'omics' to improved outcomes.
@en
prefLabel
Translating cancer 'omics' to improved outcomes.
@ast
Translating cancer 'omics' to improved outcomes.
@en
P2093
P2860
P356
P1433
P1476
Translating cancer 'omics' to improved outcomes.
@en
P2093
Carlos E Alvarez
Emily A Vucic
Keith Robison
Kelsie L Thu
Leszek A Rybaczyk
P2860
P304
P356
10.1101/GR.124354.111
P577
2012-02-01T00:00:00Z